Modeling anti-HIV compounds: the role of analogue-based approaches

Srivastava, Hemant Kumar ; Bohari, Mohammed H. ; Sastry, G. Narahari (2012) Modeling anti-HIV compounds: the role of analogue-based approaches Current Computer Aided-Drug Design, 8 (3). pp. 224-248. ISSN 1573-4099

Full text not available from this repository.

Official URL: http://www.eurekaselect.com/100500/article

Related URL: http://dx.doi.org/10.2174/157340912801619085

Abstract

There has been a tremendous progress in the development of anti-HIV therapies since the discovery of the HIV virus. Computer aided drug design in general and analogue-based approaches in particular have played an important role in the process of HIV drug discovery. Structure-based approaches also have played a vital role in this process. There are a large number of studies reported in the literature where QSAR methodology was employed to study the structural requirements for inhibition against various HIV targets like reverse transcriptase, protease, entry and integrase. The current review focuses on those studies and provides a detailed description on the QSAR methodology, descriptors, statistical significance and important findings. This review categorizes the reported QSAR studies on the basis of chemical scaffolds against a particular target. In reverse transcriptase category, QSAR studies on HEPT, TIBO, DABO, DAPY, DATA, AASBN, pyridone and DATZD derivatives have been reviewed. Cyclic urea, fullerene, AHPBA and dihydropyrone derivatives were considered in protease inhibitors category. In addition, QSAR studies on styrylquinoline, carboxylic acid, MBSA and chalcone derivatives were reviewed in integrase inhibitors category. QSAR studies on entry inhibitors like piperidine, benzyl piperidine, benzyl pyrazole, pyrrole and diazepane urea have also been reviewed.

Item Type:Article
Source:Copyright of this article belongs to Bentham Science Publishers.
Keywords:Analogue-Based Approaches; Entry Inhibitors; HIV and AIDS; Integrase Inhibitors; Protease Inhibitors; QSAR; Reverse Transcriptase Inhibitors; Linear Methods; Validation; CoMFA
ID Code:108525
Deposited On:28 Jul 2017 04:44
Last Modified:28 Jul 2017 04:44

Repository Staff Only: item control page